Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

Similar articles for PubMed (Select 12824459)

1.

The influence of finasteride on the development of prostate cancer.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr.

N Engl J Med. 2003 Jul 17;349(3):215-24. Epub 2003 Jun 24.

2.

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr.

N Engl J Med. 2004 May 27;350(22):2239-46. Erratum in: N Engl J Med. 2004 Sep 30;351(14):1470.

3.

Five-alpha-reductase Inhibitors for prostate cancer prevention.

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091. doi: 10.1002/14651858.CD007091. Review.

PMID:
18425978
4.

Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.

Ross AE, Feng Z, Pierorazio PM, Landis P, Walsh PC, Carter HB, Trock BJ, Schaeffer EM.

BJU Int. 2012 Sep;110(5):651-7. doi: 10.1111/j.1464-410X.2011.10875.x. Epub 2012 Jan 30.

PMID:
22289613
5.

Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.

Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ.

Eur Urol. 2012 Nov;62(5):757-64. doi: 10.1016/j.eururo.2012.05.025. Epub 2012 May 18.

PMID:
22658758
6.

Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial.

Etzioni RD, Howlader N, Shaw PA, Ankerst DP, Penson DF, Goodman PJ, Thompson IM.

J Urol. 2005 Sep;174(3):877-81. Erratum in: J Urol. 2005 Nov;174(5):2071.

PMID:
16093979
7.

PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer.

Kaplan SA, Roehrborn CG, Meehan AG, Liu KS, Carides AD, Binkowitz BS, Heyden NL, Vaughan ED Jr.

Urology. 2009 May;73(5):935-9. doi: 10.1016/j.urology.2008.09.079. Epub 2009 Mar 28.

PMID:
19328538
8.

Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.

Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA Jr.

J Urol. 2007 May;177(5):1749-52.

PMID:
17437804
9.

The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.

Liang Y, Ketchum NS, Louden C, Jimenez-Rios MA, Thompson IM, Camarena-Reynoso HR.

Urol Int. 2012;89(1):9-16. doi: 10.1159/000338270. Epub 2012 May 24.

PMID:
22626812
10.

Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention.

Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA Jr, Thompson IM.

Cancer Prev Res (Phila). 2008 Aug;1(3):167-73. doi: 10.1158/1940-6207.CAPR-08-0078. Epub 2008 May 18.

11.

Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.

Thompson IM, Pauler Ankerst D, Chi C, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Clin Oncol. 2007 Jul 20;25(21):3076-81.

12.

High-grade prostate cancer and finasteride.

Lebdai S, Bigot P, Azzouzi AR.

BJU Int. 2010 Feb;105(4):456-9. doi: 10.1111/j.1464-410X.2009.09089.x. Epub 2009 Nov 20. Review.

PMID:
19930174
13.

The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels.

Cote RJ, Skinner EC, Salem CE, Mertes SJ, Stanczyk FZ, Henderson BE, Pike MC, Ross RK.

Br J Cancer. 1998 Aug;78(3):413-8.

14.

Finasteride decreases the risk of prostatic intraepithelial neoplasia.

Thompson IM, Lucia MS, Redman MW, Darke A, La Rosa FG, Parnes HL, Lippman SM, Coltman CA.

J Urol. 2007 Jul;178(1):107-9; discussion 110. Epub 2007 May 11.

PMID:
17499284
15.

Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.

Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA Jr.

J Natl Cancer Inst. 2006 Aug 16;98(16):1128-33.

16.

Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.

Lucia MS, Epstein JI, Goodman PJ, Darke AK, Reuter VE, Civantos F, Tangen CM, Parnes HL, Lippman SM, La Rosa FG, Kattan MW, Crawford ED, Ford LG, Coltman CA Jr, Thompson IM.

J Natl Cancer Inst. 2007 Sep 19;99(18):1375-83. Epub 2007 Sep 11.

17.

[The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice].

Schmitz-Dräger BJ, Fischer C, Bismarck E, Dörsam HJ, Lümmen G.

Urologe A. 2007 Oct;46(10):1364, 1366-8, 1370. German.

PMID:
17874228
18.

Prostate cancer prevention and finasteride.

D'Amico AV, Barry MJ.

J Urol. 2006 Nov;176(5):2010-2; discussion 2012-3. Review.

PMID:
17070238
19.
20.

Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group.

Roehrborn CG, Boyle P, Bergner D, Gray T, Gittelman M, Shown T, Melman A, Bracken RB, deVere White R, Taylor A, Wang D, Waldstreicher J.

Urology. 1999 Oct;54(4):662-9.

PMID:
10510925
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk